...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urological Science >Preliminary experience and possible predictors of successful mirabegron treatment for overactive bladder
【24h】

Preliminary experience and possible predictors of successful mirabegron treatment for overactive bladder

机译：过度活性膀胱成功的M拉释治疗的初步经验和可能的预测因子

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The aim of this study was to report our preliminary experience of the treatment with mirabegron and to identify the predictors of a successful treatment with mirabegron in overactive bladder (OAB) patients.Materials and methods: Between October 2015 and February 2016, 234 consecutive patients (167 men and 67 women; mean age: 65.6 years; standard deviation: 16.3) diagnosed with OAB and receiving mirabegron monotherapy were enrolled retrospectively. Four weeks after mirabegron treatment, a global response assessment (GRA) was performed for all patients and analyses were performed to identify possible predictors of successful mirabegron treatment (defined as GRA > 1). Mirabegron was intended being given for at least 12 weeks. Adverse events (AEs) and reasons for discontinuing mirabegron were recorded between 4 and 12 weeks of following-up.
机译：目的：本研究的目的是报告我们对米拉巴克治疗的初步经验，并鉴定过度活性膀胱（OAB）患者中成功治疗的预测因子。2015年10月和2016年2月间，234之间的材料和方法 患者（167名男性和67名女性;意思是年龄：65.6岁;标准差：16.3）诊断患有OAB和接受M拉释单疗法的回顾性。 在M拉释治疗后四周，对所有患者进行全局响应评估（GRA），并进行分析，以确定成功的M拉伸治疗的可能预测因子（定义为GRA> 1）。 米拉巴克预期至少12周给予。 不良事件（AES）和停止乳酸的原因记录在后续4至12周之间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号